Product image of Linezolid Accord (Linezolid) supplied by GNH India

Linezolid Accord

Active Ingredient:
Linezolid
Origin:
EU

Linezolid Accord (Linezolid)

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as an intravenous formulation for IV use. It treats skin and soft tissue infections and both community‑acquired and nosocomial pneumonia caused by susceptible Gram‑positive bacteria in adult patients.
GNH India supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linezolid is indicated for infections caused by susceptible Gram‑positive bacteria, particularly in the skin, soft tissues, and respiratory tract.

  • Skin and soft tissue infections: effective against susceptible Gram‑positive organisms, reducing infection severity.
  • Community‑acquired pneumonia: treats infections caused by susceptible Gram‑positive bacteria.
  • Nosocomial pneumonia: used for hospital‑acquired pneumonia due to susceptible Gram‑positive pathogens.

How It Works

  • Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex. This action blocks translation of essential proteins, leading to bacteriostatic activity against susceptible Gram‑positive organisms, including Staphylococcus aureus and Streptococcus pneumoniae.

Side Effects

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools occurring during therapy.
  • Headache: transient cranial discomfort.
  • Vomiting: occasional emesis.
  • Metallic taste: altered taste perception.
  • Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

  • Thrombocytopenia: significant drop in platelet count requiring monitoring.
  • Anemia: reduction in red blood cell levels.
  • Peripheral neuropathy: nerve damage presenting as tingling or numbness.
  • Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
  • Optic neuritis: inflammation of the optic nerve affecting vision.
  • Lactic acidosis: rare metabolic disturbance with high morbidity.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety measures.

  • Renal impairment: monitor renal function and adjust therapy as needed.
  • Hepatic impairment: assess liver enzymes and observe for hepatotoxicity.
  • Hematologic monitoring: perform regular complete blood counts to detect cytopenias.
  • Serotonergic agents: avoid concomitant use due to risk of serotonin syndrome.
  • Pregnancy: safety unknown; use only if benefits outweigh potential risks.
  • Store at ambient temperature: keep in original packaging, protect from moisture and light.

Avoid Interactions

Linezolid interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome.
  • Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): may precipitate serotonin syndrome.
  • Rifampin: induces metabolism, reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Warfarin: may increase INR, necessitating coagulation monitoring.
  • Antacids containing magnesium or aluminum: can affect absorption, consider timing adjustments.
  • Ethanol: potential disulfiram‑like reaction, advise patient to limit alcohol intake.

Frequently Asked Questions

Linezolid Accord is used to treat skin and soft tissue infections, community‑acquired pneumonia, and nosocomial (hospital‑acquired) pneumonia caused by susceptible Gram‑positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.

Linezolid works by binding to the bacterial 50S ribosomal subunit, preventing the formation of the initiation complex needed for protein synthesis. This inhibition stops the bacteria from producing essential proteins, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms.

The specific dose and duration of Linezolid Accord are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals should follow the approved prescribing information for dosing.

The safety of Linezolid Accord in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Linezolid Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any required import documentation.

Linezolid belongs to the oxazolidinone class and offers oral and intravenous options, making it useful for resistant Gram‑positive infections, including MRSA. Compared with beta‑lactams or glycopeptides, linezolid provides a different mechanism of action and is often reserved for cases where other agents are ineffective or contraindicated.

Linezolid Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

Linezolid Accord is administered intravenously by a healthcare professional. The infusion is typically given over a set period as directed by the prescriber, and the exact administration protocol should follow institutional guidelines and the product’s prescribing information.

Serious risks include thrombocytopenia, anemia, peripheral neuropathy, optic neuritis, serotonin syndrome when combined with serotonergic drugs, and rare cases of lactic acidosis. Patients should be monitored regularly for hematologic changes and neurological symptoms throughout therapy.

Linezolid Accord should be avoided in patients with known hypersensitivity to linezolid or any component of the formulation, those taking monoamine oxidase inhibitors, or individuals with uncontrolled hypertension related to serotonergic drug interactions. Clinicians should also assess risks in patients with severe hepatic or renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linezolid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT